News
2021
-
Group Company
R&D
December 20, 2021
-
Data from Japan's First Phase II/III Clinical Trial of NANOBODY® Ozoralizumab for Rheumatoid Arthritis Presented at the 36th Annual Meeting of the Japanese Society for Clinical Rheumatology and Related Research
-
Holdings
Investors
November 9, 2021
-
The 2nd Quarter of Fiscal 2021 Financial Statements
-
Holdings
Investors
November 9, 2021
-
Reference Data of The 2nd Quarter of Fiscal 2021 Financial Statements
-
Group Company
R&D
October 25, 2021
-
Cetylpyridinium chloride hydrate (CPC) confirmed to have an action inactivating SARS-CoV-2
-
Group Company
Corporate
October 8, 2021
-
Taisho Pharmaceutical appointed as Premium Global Partner of New Zealand Rugby
-
Holdings
Investors
August 5, 2021
-
The 1st Quarter of Fiscal 2021 Financial Statements
-
Holdings
Investors
August 5, 2021
-
Reference Data of The 1st Quarter of Fiscal 2021 Financial Statements
-
Group Company
Corporate
June 30, 2021
-
Taisho and Ancora Bio sign exclusive license agreement for the development, manufacturing, and commercialization of selective vasopressin V1b receptor antagonist, TS-121, worldwide
-
Holdings
Investors
June 29, 2021
-
Notice Concerning Issuance of Stock Options (Stock Acquisition Rights)
-
Group Company
Corporate
June 24, 2021
-
Taisho Pharmaceutical appointed as Official Supplier of Rugby World Cup France 2023
-
Holdings
Corporate
May 14, 2021
-
Notice Concerning the Execution of the Share Exchange Agreement to Make Biofermin Pharmaceutical Co., Ltd. a Wholly-owned Subsidiary of Taisho Pharmaceutical Holdings Co., Ltd.
-
Holdings
Investors
May 14, 2021
-
Financial Statements for Fiscal 2020
-
Holdings
Investors
May 14, 2021
-
Reference Data
-
Group Company
R&D
March 22, 2021
-
Notification of Application for Approval to Manufacture and Market Anti-TNFα multivalent NANOBODY® compound (ozoralizumab) in Japan
Japan's first NANOBODY® Therapeutic
-
Group Company
R&D
February 22, 2021
-
Notification of Application for Approval of Manufacturing and Marketing for Orally Disintegrating Films of SGLT2 Inhibitor Lusefi® Tablets
-
Holdings
Investors
February 4, 2021
-
The 3rd Quarter of Fiscal 2020 Financial Statements
-
Holdings
Investors
February 4, 2021
-
Reference Data
-
Group Company
Corporate
January 22, 2021
-
Taisho and Chugai Terminate the Co-Marketing Agreement of Edirol®,a Treatment for Osteoporosis